PRIMA: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Niraparib significantly extends progression-free survival among patients with newly diagnosed advanced ovarian cancer post-response to platinum-based chemotherapy, regardless of homologous-recombination deficiency status.